Antimicrobial resistance of Streptococcus pneumoniae isolates of outpatients in Germany, 1999-2000

Chemotherapy
Ralf René ReinertSebastian Lemmen

Abstract

The aim of the study was to determine the prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae during the winter of 1999-2000 in Germany. Pneumococcal isolates were prospectively collected by 14 different clinical microbiology laboratories. Minimal inhibitory concentrations of penicillin G, erythromycin A, clarithromycin, roxithromycin, azithromycin, clindamycin, levofloxacin and telithromycin were determined by the broth microdilution method. Among 328 strains 4.6% were nonsusceptible to penicillin G (intermediate and resistant strains) and 9.5% were resistant to erythromycin A. Analysis of erythromycin-resistant strains for the underlying resistance determinants revealed that 12 (38.7%) belonged to the erm(B) and 19 (61.3%) to the mef(E) type of resistance. Among the macrolide-resistant strains, serotypes 19F (n = 9) and 14 (n = 8) were the predominant types. Macrolide resistance in Germany is of growing concern and mainly due to the high prevalence of pneumococci expressing the mef(E) type of resistance.

References

Apr 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Musher
Dec 26, 2001·The Journal of Antimicrobial Chemotherapy·Ralf René ReinertRudolf Lütticken
Jun 1, 2002·The Journal of Antimicrobial Chemotherapy·Ralf René ReinertFranz-Josef Schmitz
Jan 31, 2003·The Journal of Antimicrobial Chemotherapy·K P Klugman
Jan 31, 2003·The Journal of Antimicrobial Chemotherapy·J García-De-LomasC Gimeno
Jan 31, 2003·The Journal of Antimicrobial Chemotherapy·J J Canet, J Garau
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Grit Ackermann, Arne C Rodloff

❮ Previous
Next ❯

Citations

Mar 1, 2005·Current Opinion in Infectious Diseases·Grant W Waterer
Apr 26, 2007·Annals of Medicine·Keith Poole
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C NeelemanJ W Mouton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.